Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 4, 2019updated 10 Jul 2019 11:42am

Sernova reports positive data in type 1 diabetes trial

Canadian manufacturer Sernova has reported positive results from an interim analysis of a Phase I/II clinical trial assessing its Cell Pouch transplanted with islet cells in type 1 diabetes patients.

Canadian manufacturer Sernova has reported positive results from an interim analysis of a Phase I/II clinical trial assessing its Cell Pouch transplanted with islet cells in type 1 diabetes patients.

Cell Pouch is an implantable and scalable medical device that forms a natural environment in the body to house therapeutic cells and enable their long-term survival and function.

In the first trial subject, the device transplanted with islet cells met primary safety measures and clinically significant efficacy outcomes, including glucose-stimulated C-peptide and production of insulin.

Results showed no incidences of Cell Pouch-related adverse events. The device was also observed to be well-incorporated with vascularised tissue.

A 6.35kg weight reduction was found, along with stabilising improvements in all glycaemic control measures. Data further revealed a 87.5% decrease in hypoglycemic events from baseline over a monitoring period of two weeks.

In addition, stimulated blood levels of C-peptide and insulin were observed at the 90-day post-transplant point.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Principal study investigator Dr Piotr Witkowski said: “The first of two doses of islets transplanted into the Cell Pouch is showing safety and early indicators of efficacy.

“Importantly, demonstration of glucose-stimulated C-peptide and insulin present in the bloodstream is definitive proof of islet survival and function in the Cell Pouch.”

The non-randomised, unblinded, single arm Phase I/II trial is designed for patients with hypoglycaemia unawareness.

Once vascularised tissue chambers are developed within the implanted Cell Pouches, patients are stabilised on immunosuppression and then purified islets are transplanted into the device.

The primary objective of the trial is safety and tolerability of islet transplantation into the Cell Pouch, followed by efficacy as evaluated using certain defined measures.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU